Publications by authors named "Khan Nedd"

Claim this Profile
H
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Eric L Wallace, Ozlem Goker-Alpan, William R Wilcox, Myrl Holida, John Bernat, Khan Nedd

J Med Genet· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study).
Bincy Abraham, Bertus Eksteen, Khan Nedd, Hrishikesh Kale, Dipen Patel

Adv Ther· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.
Ulla Feldt-Rasmussen, Derralynn Hughes, Gere Sunder-Plassmann, Suma Shankar, Khan Nedd

Mol Genet Metab· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta.
Renuka P Limgala, Tabitha Jennelle, Matthew Plassmeyer, Michel Boutin, Pamela Lavoie, Khan Nedd

Am J Transl Res· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
Derralynn A Hughes, Kathleen Nicholls, Suma P Shankar, Gere Sunder-Plassmann, David Koeller, Khan Nedd

J Med Genet· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.
Dominique P Germain, Derralynn A Hughes, Kathleen Nicholls, Daniel G Bichet, Roberto Giugliani, Khan Nedd

N Engl J Med· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.
Ozlem Goker-Alpan, Michael J Gambello, Gustavo H B Maegawa, Khan J Nedd, Daniel J Gruskin

JIMD Rep· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa.
Ozlem Goker-Alpan, Khan Nedd, Suma P Shankar, Yeong-Hau H Lien, Neal Weinreb

JIMD Rep· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
Laura E Case, Carl Bjartmar, Claire Morgan, Robin Casey, Joel Charrow, Khan Nedd

Neuromuscul Disord· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis